Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
01 February 1991Website:
http://www.quidelortho.comNext earnings report:
07 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 20:20:00 GMTDividend
Analysts recommendations
Institutional Ownership
QDEL Latest News
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of QuidelOrtho Corporation (NASDAQ: QDEL) breached their fiduciary duties to shareholders.
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will attend three upcoming investor conferences and participate in fireside chats at all three conferences. UBS Global Healthcare Conference On Tuesday, November 12, 2024, QuidelOrtho is scheduled to part.
QDEL's strong product portfolio raises optimism about the stock.
An analyst became notably more bullish on the diagnostics company's prospects. He upgraded his recommendation from hold to buy.
QDEL's strong product portfolio raises optimism about the stock.
QDEL announces the FDA's clearance for its VITROS syphilis assay, which boosts the company's infectious disease testing portfolio.
QuidelOrtho's (QDEL) second-quarter results reflect growth in revenues. However, gross profit continues to decline.
QuidelOrtho (QDEL) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to earnings of $0.26 per share a year ago.
QuidelOrtho's (QDEL) strong product portfolio raises optimism about the stock.
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against QuidelOrtho Corporation (NASDAQ: QDEL) on behalf of long-term stockholders following a class action complaint that was filed against QuidelOrtho on April 12, 2024 with a Class Period from February 18, 2022 to April 1, 2024. Our investigation concerns whether the board of directors of QuidelOrtho have breached their fiduciary duties to the company.
What type of business is QuidelOrtho?
Quidel Corporation is a manufacturer of medical diagnostic supplies. The company produces a wide range of tests, reagents, devices, and other products for diagnosing viral and bacterial infections, autoimmune diseases, and detecting markers of inflammation. The company also produces bacterial cultures, conducts research in the field of diagnosing oncological diseases, diabetes, and so on. One of the popular solutions from Quidel is the Triage device for rapid detection of prohibited substances in patients' bodies. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.
What sector is QuidelOrtho in?
QuidelOrtho is in the Healthcare sector
What industry is QuidelOrtho in?
QuidelOrtho is in the Medical Devices industry
What country is QuidelOrtho from?
QuidelOrtho is headquartered in United States
When did QuidelOrtho go public?
QuidelOrtho initial public offering (IPO) was on 01 February 1991
What is QuidelOrtho website?
https://www.quidelortho.com
Is QuidelOrtho in the S&P 500?
No, QuidelOrtho is not included in the S&P 500 index
Is QuidelOrtho in the NASDAQ 100?
No, QuidelOrtho is not included in the NASDAQ 100 index
Is QuidelOrtho in the Dow Jones?
No, QuidelOrtho is not included in the Dow Jones index
When was QuidelOrtho the previous earnings report?
No data
When does QuidelOrtho earnings report?
The next expected earnings date for QuidelOrtho is 07 November 2024